Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NCF1 | P14598 | 1/20 | 0.46 |
| ▸ | ACHE | P22303 | 2/20 | 0.34 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.33 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.33 |
| ▸ | HTR2A | P28223 | 1/20 | 0.32 |
| ▸ | HTR2C | P28335 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22043201 | 0.81 | MEN1 (0.33) | — | |
| SCHEMBL13397459 | 0.81 | HRH3 (0.39) | HRH3 | |
| SCHEMBL13397418 | 0.81 | NCF1 (0.45) | NCF1ACHEHRH3HRH4HTR2A | |
| SCHEMBL27429927 | 0.79 | SMN1; SMN2 (0.37) | HRH3 | |
| SCHEMBL13397287 | 0.78 | NCF1 (0.42) | NCF1ACHEHRH3HRH4HTR2A | |
| SCHEMBL13397448 | 0.78 | NCF1 (0.42) | NCF1ACHEHRH3HRH4 | |
| SCHEMBL25571620 | 0.77 | NCF1 (0.54) | NCF1ACHEHRH3HRH4 | |
| SCHEMBL26267191 | 0.76 | NCF1 (0.41) | NCF1ACHEHRH3 | |
| SCHEMBL793180 | 0.75 | NCF1 (0.52) | NCF1ACHEHRH3HRH4 | |
| SCHEMBL21126641 | 0.75 | ALOX5 (0.39) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240216515-A1 | COMPOSITIONS AND METHODS FOR TARGETED DELIVERY TO CELLS | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM | 2024-07-04 | — | — | US | disclosed |
| US-20240207178-A1 | COMPOSITIONS AND METHODS FOR TARGETED DELIVERY TO CELLS | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM | 2024-06-27 | — | — | US | disclosed |
| US-20230302138-A1 | COMPOSITIONS AND METHODS FOR TARGETED DELIVERY TO CELLS | RECODE THERAPEUTICS, INC. | 2023-09-28 | — | — | US | disclosed |
| US-20230293429-A1 | COMPOSITIONS AND METHODS FOR TARGETED DELIVERY TO CELLS | RECODE THERAPEUTICS, INC. | 2023-09-21 | — | — | US | disclosed |
| US-20230293429-A1 | COMPOSITIONS AND METHODS FOR TARGETED DELIVERY TO CELLS | RECODE THERAPEUTICS, INC. | 2023-09-21 | — | — | US | disclosed |
| US-20100104659-A1 | BENZOPYRANOPYRAZOLES | 4SC AG (DE) | 2010-04-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230302138-A1 | COMPOSITIONS AND METHODS FOR TARGETED DELIVERY TO CELLS | CHMP4B, LIPA, NPC1L1 | NCF1 1278/4885ACHE 3928/4885HRH3 1656/4885 |
| US-20240207178-A1 | COMPOSITIONS AND METHODS FOR TARGETED DELIVERY TO CELLS | CHMP4B, LIPA, NPC1L1 | NCF1 1278/4885ACHE 3928/4885HRH3 1656/4885 |
| US-20240216515-A1 | COMPOSITIONS AND METHODS FOR TARGETED DELIVERY TO CELLS | PNLIP, LIPA, PHOSPHO1 | NCF1 844/4885ACHE 3809/4885HRH3 1419/4885 |
| US-20230293429-A1 | COMPOSITIONS AND METHODS FOR TARGETED DELIVERY TO CELLS | CHMP4B, LIPA, NPC1L1 | NCF1 1278/4885ACHE 3928/4885HRH3 1656/4885 |
| US-20100104659-A1 | BENZOPYRANOPYRAZOLES | BAX, BCL2, BAD | NCF1 720/4885ACHE 3418/4885HRH3 1893/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.